Tools   Select Another Resource Report Type

http://www.mayo.edu/research/centers-programs/translational-polycystic-kidney-disease-pkd-center/overview

Center that concentrates on the common, adult form of the disease, autosomal dominant PKD (ADPKD). The services provided focus on understanding the genetic basis of disease, more accurately monitoring disease progression and improving prognostics, and employing model systems to explore pathogenesis and conduct preclinical testing.

Proper citation: Translational Polycystic Kidney Disease (PKD) Center at Mayo Clinic Rochester (RRID:SCR_015313) Copy   

•   Source: SciCrunch Registry
  

http://www.rarekidneystones.org

An organization of various participants and independent efforts representing four major diseases of hereditary nephrolithiasis. The Consortium facilitates cooperative exchange of information and resources among investigators, clinicians, patients, and researchers in order to improve care and outcomes for patients with rare stone diseases. The consortium promotes ready availability of diagnostic testing, pooling of clinical experiences, and availability of tissue banks in order to advance the science.

Proper citation: Rare Kidney Stone Consortium (RKSC) (RRID:SCR_014413) Copy   

•   Source: SciCrunch Registry
  

https://www.uab.edu/medicine/obriencenter/cores/biostatistics-core

Core provides statistical expertise in the conceptualization and design of projects, expertise in data management for the resulting clinical and bioinformatics data, and assistance with the preparation of project reports, presentations and manuscripts.

Proper citation: University of Alabama at Birmingham-University of California San Diego O'Brien Center for Acute Kidney Injury Research Biostatistical Core (RRID:SCR_015283) Copy   

•   Source: SciCrunch Registry
  

http://www.utsouthwestern.edu/research/core-facilities/obrien-kidney/core-services/clinical-translational-core.html

Core whose aim is to translate basic science research into effective diagnostic and therapeutic strategies that will improve the lives of patients by interrupting the pathogenesis of chronic kidney disease and its attendant high risk of cardiovascular disability and death. It combines comprehensive human genetics with phenotyping of subjects.

Proper citation: George M. O'Brien Kidney Research Core Center - UT Southwestern Medical Center Clinical and Translational Core (RRID:SCR_015295) Copy   

•   Source: SciCrunch Registry
  

http://www.dukekidneycenter.org/cores/clinical-and-translational-core

Core facility which investigates the connections between chronic kidney disease, cardiovascular disease, and hypertension. It focuses specifically on investigating the pathophysiology, epidemiology, and therapeutic response in on-going studies or existing datasets of one of the three diseases with the aim of relating data from individual diseases to each other.

Proper citation: Duke O'Brien Center for Kidney Research Clinical and Translational Core (RRID:SCR_015272) Copy   

•   Source: SciCrunch Registry
  

http://www.kidneycenter.pitt.edu/cores/cell_physiology.html

Core that provides investigators with in vitro systems for the study of transport processes at the molecular, cell, and epithelial levels.

Proper citation: Pittsburgh Center for Kidney Research Cellular Physiology (RRID:SCR_015284) Copy   

•   Source: SciCrunch Registry
  

http://www.kidneycenter.pitt.edu/cores/single_nephron_core.html

Core that offers functional (in vitro microperfusion of isolated segments, measurements of transepithelial ion/solute fluxes, fluorescence functional imaging of single tubular cells), biochemical (microassays of enzyme/transporter activity), molecular (quantitation and analysis of RNA and protein), and analytical (targeted renal metabolomics of interrelated networks of small molecules) strategies applied to microdissected tubules, single cells, and urinary exosomes to address relevant questions proposed by users. It also provides analytical services for determining concentrations of exogenous pharmacological agents and molecular probes achieved within the tissue of interest.

Proper citation: Pittsburgh Center for Kidney Research Single Nephron and Metabolomics (RRID:SCR_015285) Copy   

•   Source: SciCrunch Registry
  

http://obriencenter.yale.edu/humangenetics.aspx

Core that provides infrastructure support for several key steps in translational research, including development of HIC protocols, patient recruitment, patient DNA extraction and archiving, tools for high throughput SNP genotyping and DNA sequencing, and analysis of genetic linkage and linkage disequilibrium.

Proper citation: George M. O'Brien Kidney Center at Yale Human Genetics and Clinical Research Core (RRID:SCR_015298) Copy   

•   Source: SciCrunch Registry
  

http://obriencenter.yale.edu/renalphyscore.aspx

Core provides specialized services and training for assessing renal function in small animals at the level of single tubules in vitro and in vivo (e.g. micropuncture, microperfusion, and tubule-specific microdissection), the whole kidney (e.g. clearance studies in anesthetized animals, perfusion fixation for histology studies), and the intact organism (e.g. balance studies in metabolic cages, acute and chronic BP measurements).

Proper citation: George M. O'Brien Kidney Center at Yale Renal Physiology Core (RRID:SCR_015296) Copy   

•   Source: SciCrunch Registry
  

http://archives.niddk.nih.gov/patient/aask/aask.aspx

Clinical trial investigating whether a specific class of antihypertensive drugs (beta-adrenergic blockers, calcium channel blockers, or angiotensin converting enzyme inhibitors) and/or the level of blood pressure would influence progression of hypertensive kidney disease in African Americans. The initiative consisting of 21 clinical centers and a data-coordinating center is followed by a Continuation of AASK Cohort Study to investigate the environmental, socio-economic, genetic, physiologic, and other co-morbid factors that influence progression of kidney disease in a well-characterized cohort of African Americans with hypertensive kidney disease. Only patients who were previously in the randomized trial are eligible for the cohort study. A significant discovery was made in the treatment strategy for slowing kidney disease caused by hypertension. Angiotensin-converting enzyme (ACE) inhibitors, compared with calcium channel blockers, were found to slow kidney disease progression by 36 percent, and they drastically reduced the risk of kidney failure by 48 percent in patients who had at least one gram of protein in the urine, a sign of kidney failure. ACE inhibitors have been the preferred treatment for hypertension caused by diabetes since 1994; however, calcium channel blockers have been particularly effective in controlling blood pressure in African Americans. The AASK study now recommends ACE inhibitors to protect the kidneys from the damaging effects of hypertension. The Continuation of AASK Cohort Study will be followed at the clinical centers. The patients will be provided with the usual clinical care given to all such patients at the respective centers. Baseline demographic information, selected laboratory tests, and other studies are being obtained at the initiation of the Continuation Study. The patients will be seen quarterly at the centers, and some selected studies done at these visits. Samples will be obtained and stored for additional studies and analyses at a later date.

Proper citation: AASK Clinical Trial and Cohort Study (RRID:SCR_006985) Copy   

•   Source: SciCrunch Registry
  

http://rgd.mcw.edu/rgdCuration/?module=portal&func=show&name=renal

An integrated resource for information on genes, QTLs and strains associated with a variety of kidney and renal system conditions such as Renal Hypertension, Polycystic Kidney Disease and Renal Insufficiency, as well as Kidney Neoplasms.

Proper citation: Renal Disease Portal (RRID:SCR_009030) Copy   

•   Source: SciCrunch Registry
  

https://www.cincinnatichildrens.org/research/divisions/n/nephrology/center-of-excellence

Center whose goal is to support basic, translational, and clinical research on critical pediatric kidney diseases by focusing on Acute Kidney Injury, Nephrotic Syndrome, and Lupus Nephritis.

Proper citation: Pediatric Centers of Excellence in Nephrology at Cincinnati Children's Hospital Medical Center (RRID:SCR_015302) Copy   

•   Source: SciCrunch Registry
  

http://www.perl-study.org

PERL is a clinical trial for people with type 1 diabetes who have early signs of kidney problems. Its goal is to test a new way to reduce loss of kidney function using a safe and inexpensive medicine.

Proper citation: Preventing Early Renal Loss in Diabetes (PERL) (RRID:SCR_015862) Copy   

•   Source: SciCrunch Registry
  

http://clinicaltrials.gov/show/NCT00271999

Randomized controlled clinical trial where subjects will be randomized to conventional hemodialysis delivered three days per week home arm or to the six times per week nocturnal home hemodialysis arm which will follow any dialysis prescription provided their prescribed standardized Kt/V is at least 4.0 and treatment time is at least 6.0 hours, six times per week. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 12 months. Primary Outcome Measures: * composite of 12 month mortality and the change over 12 months in left ventricular mass by cine-MRI, * a composite of 12 month mortality and the change over 12 months in the SF-36 RAND physical health composite Secondary Outcome Measures: * cardiovascular structure/funct (change in LV mass over 12 mos), health-related QoL/phys funct (change over 12 mos in PHC), * depression / dis burden (change over 12 mos in Beck Depression Inv.), nutrition (change over 12 mos in serum albumin, cognitive funct (change over 12 mos in TrailMaking Test B), mineral metabolism (change over 12 mos in aveg pre-dialysis serum phosphorus), * clin events (rate of non-access hospital or death * hypertension, anemia

Proper citation: Frequent Hemodialysis Network Nocturnal Trial (RRID:SCR_007014) Copy   

•   Source: SciCrunch Registry
  

https://clinicaltrials.gov/study/NCT01885559

Consortium established to design and implement clinical trials of treatments that might slow the progressive loss of renal function in Polycystic Kidney Disease (PKD). Two multicenter randomized, double-blind, placebo controlled clinical trials are running concurrently to study the efficacy of renin-angiotensin-aldosterone system blockade on the progression of cystic disease (kidney volume) and on the decline in renal function in autosomal dominant polycystic kidney disease (ADPKD). Study A is to study whether intensive ACE-I/ARB blockade decrease the progression of cystic disease compared to ACE-I monotherapy patients with early disease, relatively preserved renal function, and high-normal BP or hypertension. Study B is to study whether intensive ACE-I/ARB blockade as compared to ACE-I monotherapy slow the decline in kidney function, end-stage of renal disease, or death in the setting of standard blood pressure control in hypertensive patients with moderately advanced disease.

Proper citation: HALT PKD (RRID:SCR_001529) Copy   

•   Source: SciCrunch Registry
  

http://medicine.iupui.edu/neph/obrien/probe

Core facility which develops and characterizes methods for expressing fluorescent biosensors in the rodent kidney to be paried with intravital microscopy.

Proper citation: Indiana O'Brien Center for Advanced Microscopic Analysis Probe Delivery Core (RRID:SCR_015274) Copy   

•   Source: SciCrunch Registry
  

http://www.uab.edu/medicine/hrfdcc/

Center that focuses on understanding the causes of Cystic Kidney Disease and other related disorder and the development of new therapeutic strategies.

Proper citation: UAB Hepatorenal Fibrocystic Diseases Core Center (RRID:SCR_015311) Copy   

•   Source: SciCrunch Registry
  

https://repository.niddk.nih.gov/study/44

Randomized controlled clinical trial to understand how increasing hemodialysis to six times a week from the standard of three times a week may result in improved heart health. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 1 year. Subjects will be randomized to either conventional hemodialyis Daily HD delivered for at least 2.5 hours (typically 3 to 4 hours), 3 days per week, or to more frequent hemodialysis delivered for 1.5 - 2.75 hours, 6 days per week. The study has two co-primary outcomes: 1) a composite of mortality with the change over 12 months in left ventricular mass by magnetic resonance imaging, and 2) a composite of mortality with the change over 12 months in the SF-36 RAND physical health composite (PHC) quality of life scale. In addition, main secondary outcomes have been designated for each of seven outcome domains: 1) cardiovascular structure and function (change in LV mass), 2) health-related quality of life/physical function (change in the PHC), 3) depression/burden of illness (change in Beck Depression Inventory), 4) nutrition (change in serum albumin), 5) cognitive function (change in the Trail Making Test B), 6) mineral metabolism (change in average predialysis serum phosphorus), and 7) clinical events (rate of non-access hospitalization or death). Hypertension and anemia are also main outcome domains, but without designation of single first priority outcomes.

Proper citation: Frequent Hemodialysis Network Daily Trial (RRID:SCR_001527) Copy   

•   Source: SciCrunch Registry
  

http://medicine.iupui.edu/neph/obrien/

Imaging center which provides renal and urological researchers access to intravital optical microscopy and 3-dimensional quantitative digital image analysis.

Proper citation: Indiana O'Brien Center for Advanced Microscopic Analysis (RRID:SCR_015271) Copy   

•   Source: SciCrunch Registry
  

http://drc.ucsf.edu/

One of sixteen research centers established by the National Institute of Diabetes and Digestive and Kidney Diseases that fosters research and training in the areas of diabetes and related endocrine and metabolic disorders.

Proper citation: University of California San Francisco Diabetes Research Center (RRID:SCR_015102) Copy   

•   Source: SciCrunch Registry